Xact Kapitalforvaltning AB Buys Shares of 2,465 Loxo Oncology (LOXO)

Xact Kapitalforvaltning AB bought a new stake in shares of Loxo Oncology (NASDAQ:LOXO) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 2,465 shares of the biopharmaceutical company’s stock, valued at approximately $208,000.

A number of other large investors have also bought and sold shares of the business. New York State Common Retirement Fund grew its holdings in shares of Loxo Oncology by 2.9% during the third quarter. New York State Common Retirement Fund now owns 25,097 shares of the biopharmaceutical company’s stock worth $2,312,000 after buying an additional 700 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Loxo Oncology by 3.4% during the third quarter. Bank of New York Mellon Corp now owns 121,558 shares of the biopharmaceutical company’s stock worth $11,198,000 after buying an additional 4,018 shares in the last quarter. Great West Life Assurance Co. Can grew its holdings in shares of Loxo Oncology by 195.8% during the third quarter. Great West Life Assurance Co. Can now owns 2,958 shares of the biopharmaceutical company’s stock worth $275,000 after buying an additional 1,958 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Loxo Oncology by 160.1% during the third quarter. Legal & General Group Plc now owns 13,042 shares of the biopharmaceutical company’s stock worth $1,198,000 after buying an additional 8,028 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in shares of Loxo Oncology by 12.0% during the third quarter. Wells Fargo & Company MN now owns 18,028 shares of the biopharmaceutical company’s stock worth $1,661,000 after buying an additional 1,933 shares in the last quarter.

How to Become a New Pot Stock Millionaire

In other news, VP Jennifer Burstein sold 1,700 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $93.24, for a total transaction of $158,508.00. Following the transaction, the vice president now directly owns 1,700 shares of the company’s stock, valued at $158,508. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Avi Z. Naider sold 15,000 shares of the business’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $100.00, for a total transaction of $1,500,000.00. Following the transaction, the director now directly owns 141,118 shares in the company, valued at $14,111,800. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 54,564 shares of company stock worth $6,005,345. 27.80% of the stock is currently owned by corporate insiders.

LOXO opened at $134.07 on Thursday. Loxo Oncology has a 1 year low of $42.11 and a 1 year high of $138.54. The company has a market capitalization of $4,008.06, a P/E ratio of -25.25 and a beta of 2.32.

Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.53. The business had revenue of $21.30 million for the quarter. analysts anticipate that Loxo Oncology will post 0.3 EPS for the current fiscal year.

A number of brokerages have recently commented on LOXO. William Blair reiterated a “buy” rating on shares of Loxo Oncology in a report on Monday. Morgan Stanley upgraded shares of Loxo Oncology from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $130.00 to $170.00 in a report on Monday. ValuEngine upgraded shares of Loxo Oncology from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Zacks Investment Research upgraded shares of Loxo Oncology from a “hold” rating to a “buy” rating and set a $148.00 price target for the company in a report on Friday, March 9th. Finally, BidaskClub upgraded shares of Loxo Oncology from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 24th. Twelve equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $131.89.

WARNING: “Xact Kapitalforvaltning AB Buys Shares of 2,465 Loxo Oncology (LOXO)” was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/04/19/xact-kapitalforvaltning-ab-buys-shares-of-2465-loxo-oncology-loxo.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply